Soon-Shiong explained that N-803 had also proven effective in a first-in-human immunotherapy clinical trial combining an IL-15 superagonist with NantKwest’s off-the-shelf, PD-L1 tumor-targeted NK cells (NCT04050709) in a patient with metastatic pancreatic cancer who had relapsed after prior standard-of-care therapy. He anticipates “broad, universal treatments across tumor types, avoiding high-dose chemotherapy and radiation.”